Invesco’s Tourmaline Bio TRML Stock Holding History

Invesco’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,558	Closed	-$1.46M	–	3866
2025 Q3	$1.46M	Buy	30,558 +4,932	+19%	+$137K	﹤0.01%	2750
2025 Q2	$410K	Buy	25,626 +5,706	+29%	+$92.4K	﹤0.01%	3251
2025 Q1	$303K	Buy	19,920 +7,765	+64%	+$124K	﹤0.01%	3356
2024 Q4	$247K	Buy	12,155 +1,181	+11%	+$29.7K	﹤0.01%	3471
2024 Q3	$282K	Sell	10,974 -885	-7%	-$14.8K	﹤0.01%	3437
2024 Q2	$153K	Sell	11,859 -115,045	-91%	-$1.85M	﹤0.01%	3693
2024 Q1	$2.91M	Buy	+126,904	New	+$4.47M	﹤0.01%	2502

Invesco's TRML Position: Q4 2025 in Review

Invesco sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 30,558 shares — an estimated $1.46M sold.

Invesco first reported a position in TRML in Q1 2024 and held it in 7 quarters. The position peaked at $2.91M in Q1 2024. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Invesco reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Invesco sold 30,558 Tourmaline Bio shares in Q4 2025, an estimated $1.46M.
Invesco first reported a position in Tourmaline Bio in Q1 2024 and held it in 7 quarters.
Invesco's Tourmaline Bio position peaked at $2.91M in Q1 2024.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Invesco's 13F filing for Q4 2025, filed 19 Feb 2026.